Nomura Holdings (NMR) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
There is no meaningful price-target consensus for Nomura Holdings (NMR): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. What does exist is an earnings forecast. For the fiscal year ending Mar 2027, the 4 analysts publishing estimates on NMR expect earnings of $1.00 per share (+29% on the year before) and revenue of 2.5 trillion JPY (+252%). The full quarter and fiscal-year estimates are below, with the drivers and risks that decide whether they are met. Walnut is not an investment adviser.
Why NMR has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. NMR is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.
All operating figures originate in Japanese yen and are translated here at ~JPY 159 per US dollar (Federal Reserve H.10, mid-August 2026); Nomura itself translated its June 2026 quarter at ~JPY 162.61, the New York noon buying rate on June 30, 2026, so published dollar equivalents vary with the rate chosen. One ADS equals one common share, which keeps the ADR arithmetic simple: the ~$27.2 billion capitalisation in October 2026 is just the Tokyo price converted. Yahoo shows a trailing ADR dividend yield of about 3.5% as of October 2026, but ADR distributions arrive net of Japanese withholding tax and are converted at payment-date rates, so the cash a US holder receives can differ from the yen-denominated figure. September-quarter results arrive on October 28, 2026.
NMR earnings and revenue forecast
For the fiscal year ending Mar 2027, the 4 analysts publishing estimates on NMR expect earnings of $1.00 per share (+29% on the year before) and revenue of 2.5 trillion JPY (+252%).
| Period | EPS estimate | EPS growth | Revenue estimate | Revenue growth |
|---|---|---|---|---|
Quarter ending Dec 2026 next quarter to report, 1 analyst | $0.22 | +9.1% | 661 billion JPY | +20% |
Quarter ending Mar 2027 the quarter after, 1 analyst | $0.23 | +45% | 666.2 billion JPY | +15% |
Fiscal year ending Mar 2027 fiscal year next to report, 4 analysts | $1.00 | +29% | 2.5 trillion JPY 2.4 trillion JPY to 2.5 trillion JPY | +252% |
Fiscal year ending Mar 2028 the fiscal year after, 5 analysts | $0.96 | -3.8% | 2.5 trillion JPY 2.3 trillion JPY to 2.7 trillion JPY | +1.3% |
Consensus estimates for NMR published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.
Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Nomura Holdings next reports around January 29, 2027 (an estimated date), which is when these figures get tested against actual results.
Is there a 2030 forecast for NMR?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering NMR do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
The furthest-out consensus that exists is for the fiscal year ending Mar 2028: analysts expect earnings of $0.96 per share, -3.8% on the fiscal year ending Mar 2027 estimate of $1.00. Beyond that, nobody publishes estimates, so any later number is an extrapolation.
On the figures we hold as of November 2026, NMR trades at about 10.9 times trailing earnings and 16.9 times forward earnings. A forward multiple at or above the trailing one means the market is not pricing in earnings growth over the next year. Keep that in mind before assuming a long-horizon rise.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Nomura Holdings can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move NMR from here
In short: the drivers cited most often are Wealth Management is being rebuilt around recurring fees, Asset management scale after the Macquarie purchase, Wholesale is finally covering its cost base. The risk cited most often against it is wholesale revenue is genuinely cyclical, and a year of record trading results is a poor guide to the next one; Nomura has posted losing years in this division within recent memory.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the NMR is it a buy page.
Your questions about Nomura Holdings
Ask Walnut's AI anything about NMR and see how it fits what you own.
FAQ
What is the price target for Nomura Holdings (NMR)?
+
There is no meaningful consensus price target for NMR, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Is there an analyst forecast for NMR?
+
For earnings, yes; for the share price, not a meaningful one. For the fiscal year ending Mar 2027, the 4 analysts publishing estimates on NMR expect earnings of $1.00 per share (+29% on the year before) and revenue of 2.5 trillion JPY (+252%). Fewer analysts publish a price target on NMR than publish earnings estimates, which is common for smaller and newer companies, and a lack of target coverage says nothing about the business itself.
What are analysts' earnings estimates for Nomura Holdings (NMR)?
+
For the fiscal year ending Mar 2027, the 4 analysts publishing estimates on NMR expect earnings of $1.00 per share (+29% on the year before) and revenue of 2.5 trillion JPY (+252%). For the fiscal year ending Mar 2028, the consensus is $0.96 per share, -3.8% on the year before. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.
When does NMR report earnings next?
+
Nomura Holdings's next earnings report is expected around January 29, 2027, a date estimated from its reporting history that the company has not yet confirmed. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.
What could move NMR?
+
The drivers and the risks are laid out on this page and in more depth on the NMR "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.